<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Volume Spike Investor &#187; United Therapeutics</title>
	<atom:link href="http://vsinvestor.com/tag/united-therapeutics/feed" rel="self" type="application/rss+xml" />
	<link>http://vsinvestor.com</link>
	<description>Investing in stocks based on short term spikes in volume</description>
	<lastBuildDate>Sat, 05 Nov 2011 14:20:15 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2</generator>
		<item>
		<title>Price/Volume Tank Alert: United Therapeutics (UTHR)</title>
		<link>http://vsinvestor.com/2008/11/pricevolume-tank-alert-united-therapeutics-uthr.html</link>
		<comments>http://vsinvestor.com/2008/11/pricevolume-tank-alert-united-therapeutics-uthr.html#comments</comments>
		<pubDate>Mon, 17 Nov 2008 14:32:52 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[General]]></category>
		<category><![CDATA[United Therapeutics]]></category>
		<category><![CDATA[UTHR]]></category>

		<guid isPermaLink="false">http://www.vsinvestor.com/?p=387</guid>
		<description><![CDATA[United Therapeutics (NASDAQ: UTHR) is down sharply this morning on news that the company&#8217;s pulmonary arterial hypertension product failed to meet its primary objectives.  The company did say this will merit ongoing studies and Eli Lilly (NYSE: LLY) has licensed the rights to UTHR for $150 million in an equity stake. UTHR is trading down [...]]]></description>
			<content:encoded><![CDATA[<p>United Therapeutics (NASDAQ: UTHR) is down sharply this morning on news that the company&#8217;s pulmonary arterial hypertension product failed to meet its primary objectives.  The company did say this will merit ongoing studies and Eli Lilly (NYSE: LLY) has licensed the rights to UTHR for $150 million in an equity stake.</p>
<p>UTHR is trading down sharply on active volume this morning.  As of 8:34 AM EST we have seen over 400,000 shares trade hands, and the last print was down a sharp 29% at $63.70.</p>
<p>Average volume on a normal day is about 660,000 shares, so it is likely that we will see an average day&#8217;s worth of trading volume occur even before the opening bell.  This is a new 52-week low as teh prior 52-week trading range was $72.55 to $117.82.</p>
<p>JON OGG<br />
NOV. 17, 2008</p>
]]></content:encoded>
			<wfw:commentRss>http://vsinvestor.com/2008/11/pricevolume-tank-alert-united-therapeutics-uthr.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

